Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 10,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $78.64, for a total transaction of $786,400.00. Following the completion of the sale, the chief executive officer owned 708,719 shares of the company’s stock, valued at approximately $55,733,662.16. This represents a 1.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Helen Torley also recently made the following trade(s):

• On Tuesday, February 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00.
• On Monday, December 1st, Helen Torley sold 16,569 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $68.92, for a total transaction of $1,141,935.48.
• On Tuesday, November 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.13, for a total value of $1,382,600.00.

Halozyme Therapeutics Stock Up 0.6%

NASDAQ HALO traded up $0.49 during midday trading on Thursday, hitting $78.42. 2,481,744 shares of the company traded hands, compared to its average volume of 1,709,236. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $79.50. The company’s 50-day simple moving average is $69.23 and its 200-day simple moving average is $68.91. The company has a market cap of $9.22 billion, a PE ratio of 16.51, a price-to-earnings-growth ratio of 0.32 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The firm had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. During the same period in the prior year, the business posted $1.27 EPS. The firm’s quarterly revenue was up 22.1% on a year-over-year basis. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a report on Monday, October 27th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Finally, Morgan Stanley lowered their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $78.80.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. DLD Asset Management LP acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $650,250,000. Arrowstreet Capital Limited Partnership raised its position in Halozyme Therapeutics by 127.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock valued at $132,192,000 after acquiring an additional 1,425,674 shares in the last quarter. Federated Hermes Inc. lifted its holdings in Halozyme Therapeutics by 294.1% in the third quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after acquiring an additional 1,082,638 shares during the period. Voloridge Investment Management LLC purchased a new stake in Halozyme Therapeutics in the 3rd quarter worth approximately $77,587,000. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $51,295,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised a slate of quarterly and annual EPS estimates (notably Q1 2026 to $1.42 from $1.19, Q2 2026 to $1.80 from $1.49, Q3 2026 to $1.83 from $1.70, Q4 2026 to $2.38 from $1.84 and FY2026 to $7.43 from $6.22), signaling stronger expected profitability and supporting forward valuation. (summary of Zacks Research estimate updates)
• Positive Sentiment: An analyst raised Halozyme’s Q1 EPS forecast, which reinforces the near‑term beat narrative and likely contributed to buying interest. Q1 EPS Forecast for Halozyme Therapeutics Raised by Analyst
• Positive Sentiment: Zacks published a positive style/value write‑up describing HALO as a top long‑term value stock, which can attract value‑oriented and institutional buyers. Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Zacks trimmed its Q3 2027 estimate slightly (to $1.99 from $2.02); the change is minor relative to the larger upward revisions and unlikely to meaningfully reverse the positive sentiment unless further downgrades follow. (summary of Zacks Research estimate change)

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.